Stevanato Group has secured €200 million in financing to support capital expenditure projects in Italy and the United States, enabling expanded production capacity for pre-filled syringes and other advanced drug delivery systems.

The funding, announced this week, comes through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. It will be used to further the company’s manufacturing capabilities in Cisterna di Latina, Italy, and Fishers, Indiana, USA — two key sites supporting growing demand for biologics-related drug containment and delivery solutions.

The investment will help scale up production of pre-filled syringes and support future capacity for ready-to-use (RTU) cartridges in Italy. In the US, the funds will support completion of the device manufacturing facility in Fishers and boost syringe output across the company’s network.

CDP committed €50 million specifically for enhancing production at the Italian plant. BNL BNP Paribas and Banco BPM contributed €100 million and €50 million respectively to support the broader expansion plan spanning both continents.

“These agreements are an important element to Stevanato Group’s financial strategy, allowing us to capitalize on robust customer demand and support the company’s long-term growth objectives,” said Marco Dal Lago, chief financial officer of Stevanato Group.

The Cisterna di Latina site focuses on RTU drug containment solutions, which are increasingly sought after for biologic and injectable therapies due to their efficiency in sterile manufacturing workflows. The Fishers site, once operational, will bolster the company’s footprint in North America and expand its device capabilities.

Stevanato Group’s expanded facilities will serve a growing pipeline of injectable therapeutics, including high-value biologics requiring sophisticated primary packaging and delivery systems.

Representatives from each lending institution underscored their support for strategic manufacturing investments within the life sciences sector. CDP, in particular, pointed to the importance of pharmaceutical innovation and its contribution to national economic growth, while BNL BNP Paribas and Banco BPM emphasised the company’s industrial relevance and global positioning.

Stevanato Group provides integrated drug containment, delivery and diagnostics platforms, working with global biopharmaceutical customers across the development and commercialization cycle.